Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.46), $0.62 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $21.26 million versus the consensus estimate of $24.34 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.